front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 | 27|28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |review

Evidence-based guidelines for the management of individuals with Factor V Leiden mutations are not yet available. Therefore, it is recommended that benefits and risks of various clinical options be discussed with patients, and their preferences considered in genetic testing decisions. Most individuals did not have adequate knowledge about Factor V Leiden mutations. Possible improvements include obtaining written consent for genetic testing, better communication with patients to confer genetic test results, evaluation of healthcare provider training about Factor V Leiden, and better tools for educating patients, including specialized thrombosis clinics, printed material and internet-based programs.